Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Beijing Centergate Technologies (holding) Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.63 |
52 Week High | CN¥6.52 |
52 Week Low | CN¥3.27 |
Beta | 0.63 |
11 Month Change | -8.33% |
3 Month Change | -21.94% |
1 Year Change | -36.87% |
33 Year Change | -46.06% |
5 Year Change | -61.13% |
Change since IPO | -59.80% |
Recent News & Updates
Recent updates
Shareholder Returns
000931 | CN Real Estate | CN Market | |
---|---|---|---|
7D | 2.3% | 1.4% | -1.5% |
1Y | -36.9% | -25.8% | -18.3% |
Return vs Industry: 000931 underperformed the CN Real Estate industry which returned -26.5% over the past year.
Return vs Market: 000931 underperformed the CN Market which returned -18.5% over the past year.
Price Volatility
000931 volatility | |
---|---|
000931 Average Weekly Movement | 6.4% |
Real Estate Industry Average Movement | 7.3% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000931's share price has been volatile over the past 3 months.
Volatility Over Time: 000931's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,434 | Zhanjun Hou | www.centek.com.cn |
Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical production and sales, construction, real estate development, and property management businesses in China and internationally. The company offers huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, naloxone hydrochloride, five plus biochemical, and aramol quramado tablets and capsules.
Beijing Centergate Technologies (holding) Co., Ltd. Fundamentals Summary
000931 fundamental statistics | |
---|---|
Market cap | CN¥2.73b |
Earnings (TTM) | CN¥50.95m |
Revenue (TTM) | CN¥2.29b |
51.1x
P/E Ratio1.1x
P/S RatioIs 000931 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
000931 income statement (TTM) | |
---|---|
Revenue | CN¥2.29b |
Cost of Revenue | CN¥935.34m |
Gross Profit | CN¥1.36b |
Other Expenses | CN¥1.31b |
Earnings | CN¥50.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 0.068 |
Gross Margin | 59.24% |
Net Profit Margin | 2.22% |
Debt/Equity Ratio | 35.4% |
How did 000931 perform over the long term?
See historical performance and comparison